Leuko is a Massachusetts company developing PointCheck, a fingertip device that checks white blood cell levels without a blood test, so people having chemotherapy can be warned at home when their infection risk is high.
Leuko Labs, Inc., an MIT spin-out in Cambridge, Massachusetts, is developing PointCheck, an investigational noninvasive device that shines light into the skin near the fingernail, images blood flow in superficial capillaries and uses AI to assess whether white blood cell levels are dangerously low. The company says it is backed by a Series A round and NIH and NCI SBIR funding. In fiscal year 2026 the National Cancer Institute funded its SBIR project on reducing febrile neutropenia in people treated with chemotherapy with PointCheck (5R44CA228920-06, USD 991,877).
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 5R44CA228920-06: Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer | 2026 | $992K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
PointCheck is an investigational fingertip device from Leuko that checks for dangerously low white blood cell counts without a blood draw, for people having chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/